19:41 , Jun 2, 2017 |  BioCentury  |  Product Development

Ears wide open

Based on unmet need alone, hearing loss should have been every bit as attractive to investors and drug developers as ophthalmic diseases, which entered a renaissance in the mid-2000s resulting in a multibillion-dollar market for...
07:00 , Aug 13, 2015 |  BC Innovations  |  Tools & Techniques

Helping Beethoven hear

Little progress has been made in developing therapies for hearing loss that go beyond the temporary and partial solutions provided by hearing aids and cochlear implants, and most company activity is focused on acquired forms...
07:00 , Apr 22, 2013 |  BioCentury  |  Finance

The audiophiles

Sofinnova Partners and Sofinnova Ventures think audiology is the next ophthalmology - a former backwater that has become an investable space. Last week, the VCs came in as new investors in a CHF47.1 million ($50.7...
07:00 , May 15, 1995 |  BC Week In Review  |  Company News

Pharma Mar S.A. deal

The Pasteur Institute (Paris) agreed to evaluate Pharma Mar's Dehydrodidemnin B (DDB) to modulate the immune system to fight HIV infection. The in vitro studies will evaluate the drug's effect on modulation of peripheral lymphocytes,...